TRCT
CRNX

Tower Research Capital (TRC)’s Crinetics Pharmaceuticals CRNX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Sell
3,895
-2,860
-42% -$106K ﹤0.01% 1924
2026
Q1 		$245K Buy
6,755
+632
+10% +$28.2K 0.01% 1452
2025
Q4 		$285K Buy
6,123
+3,263
+114% +$145K 0.01% 1184
2025
Q3 		$119K Sell
2,860
-9,908
-78% -$317K ﹤0.01% 1861
2025
Q2 		$367K Buy
12,768
+12,235
+2,295% +$378K 0.01% 1238
2025
Q1 		$17.9K Sell
533
-6,879
-93% -$257K ﹤0.01% 3084
2024
Q4 		$379K Buy
7,412
+6,960
+1,540% +$389K 0.01% 1251
2024
Q3 		$23.1K Sell
452
-12,404
-96% -$640K ﹤0.01% 3163
2024
Q2 		$576K Buy
12,856
+12,281
+2,136% +$567K 0.01% 1223
2024
Q1 		$26.9K Sell
575
-3,028
-84% -$118K ﹤0.01% 2740
2023
Q4 		$128K Buy
3,603
+2,039
+130% +$62.5K ﹤0.01% 2442
2023
Q3 		$46.5K Sell
1,564
-2,980
-66% -$61.4K ﹤0.01% 2608
2023
Q2 		$81.9K Buy
4,544
+2,617
+136% +$52.2K ﹤0.01% 2190
2023
Q1 		$31K Buy
1,927
+1,009
+110% +$18.7K ﹤0.01% 2948
2022
Q4 		$17K Sell
918
-9,271
-91% -$163K ﹤0.01% 3264
2022
Q3 		$200K Buy
10,189
+5,687
+126% +$116K ﹤0.01% 1928
2022
Q2 		$84K Sell
4,502
-12,242
-73% -$244K ﹤0.01% 2420
2022
Q1 		$368K Buy
16,744
+13,226
+376% +$268K ﹤0.01% 1337
2021
Q4 		$100K Sell
3,518
-247
-7% -$6.09K ﹤0.01% 2220
2021
Q3 		$79K Buy
3,765
+1,881
+100% +$39.3K ﹤0.01% 2595
2021
Q2 		$36K Buy
1,884
+1,233
+189% +$21.7K ﹤0.01% 3296
2021
Q1 		$10K Sell
651
-5,422
-89% -$84K ﹤0.01% 4359
2020
Q4 		$86K Sell
6,073
-16,811
-73% -$234K ﹤0.01% 2495
2020
Q3 		$359K Buy
22,884
+19,582
+593% +$299K ﹤0.01% 2017
2020
Q2 		$58K Buy
+3,302
New +$56.3K ﹤0.01% 2930
2019
Q4 		– Sell
-2,691
Closed -$40K – 3661
2019
Q3 		$40K Buy
2,691
+2,194
+441% +$42.7K ﹤0.01% 1955
2019
Q2 		$12K Sell
497
-572
-54% -$14.2K ﹤0.01% 2448
2019
Q1 		$24K Sell
1,069
-739
-41% -$18.2K ﹤0.01% 2161
2018
Q4 		$54K Buy
+1,808
New +$50.9K ﹤0.01% 1242

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s CRNX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Crinetics Pharmaceuticals (CRNX) stake by 42% in Q2 2026, selling an estimated $106K and leaving 3,895 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #1924.

Tower Research Capital (TRC) first reported a position in CRNX in Q4 2018 and has held it in 29 quarters since. The position peaked at $576K in Q2 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Tower Research Capital (TRC) held 3,895 shares of Crinetics Pharmaceuticals worth $146K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,860 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $106K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1924 holding.
  • Tower Research Capital (TRC) first reported a position in Crinetics Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Crinetics Pharmaceuticals position peaked at $576K in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.